A study to evaluate the rate and type of adverse effects and the frequency of disease flares after COVID-19 vaccination and reasons for vaccination hesitancy in systemic rheumatic diseases patients
Latest Information Update: 08 Feb 2022
At a glance
- Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 08 Feb 2022 New trial record
- 01 Jan 2022 Results published in the Rheumatology International